Daily non-political popular news in brief.

The release of new data from the HVTN 502 HIV vaccine study

11-07-2007 · EurekAlert!

The new analyses revealed today from the STEP HIV vaccine clinical trial are both disappointing and puzzling. At this time, the data offer no clear explanations as to why the vaccine showed no measurable efficacy or why among individuals with background immunity to the adenovirus vector, there were more HIV infections in the vaccinees as compared to those in the placebo group. Analyses of the STEP data are continuing, and it will take some time before we fully understand these results.

Keywords: release, data, hvtn, 502, hiv, vaccine, study

« Previous | Next »

Similar news on "The release of new data from the HVTN 502 HIV vaccine study":

Tip sheet: Annals of Internal Medicine, Jan. 16, 2007, issue
01-15-2007 · EurekAlert!
The following articles are featured in the Jan. 16, 2007, issue of Annals of Internal Medicine tip sheet: "Review: Growth Hormone Doesn't Prevent or Reverse Changes of Aging in Healthy Elderly People and May Have Bad Side Effects," "Narcotics Are Often Prescribed for Back Pain but Efficacy Data are Poor and Chances for Abuse High New Review Finds" and "In Danish Study, Survival of People with HIV Has Improved in Recent Years."
Similar news · Read more »
Does treating worms in people with HIV slow progression to AIDS?
12-18-2007 · EurekAlert!
There is evidence that co-infection of Helminth worms may result in a more rapid progression of HIV infection to AIDS. Does treating these worms ("de-worming") slow down this progression? In a new study published in PLoS Neglected Tropical Diseases, researchers set out to answer this question. Their study found that there were simply not enough data to make any firm conclusions, and they call for larger, well-designed studies to help come to a definitive answer.
Similar news · Read more »
Novel genetics research advances possibility of HIV vaccine
07-05-2007 · EurekAlert!
A pioneering collaborative study has discovered how the HIV virus evades the human body's immune system. The research collaborative -- involving scientists from the British Columbia Centre for Excellence in HIV/AIDS, Massachusetts General Hospital, Microsoft Research and Los Alamos National Laboratory -- used highly computer-intensive, cutting-edge statistical research methods to investigate how the HIV virus mutates to escape the body's immune system.
Similar news · Read more »
First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
07-19-2007 · EurekAlert!
The first genome-wide association study of an infectious disease, conducted by an international group of researchers through the Center for HIV/AIDS Vaccine Immunology, has yielded a new understanding of why some people can suppress virus levels following HIV infection. "The clearer picture of host responses to the virus achieved through this examination of genomes could lead to improved HIV therapies and provides new targets for vaccine developers," says Elias A. Zerhouni, M.D., director of the National Institutes of Health.
Similar news · Read more »
STEP HIV vaccine study to be unblinded
11-13-2007 · EurekAlert!
Merck & Co., Inc. and the HIV Vaccine Trials Network today announced that study volunteers in the STEP study of Merck's HIV vaccine will be told whether they received vaccine or placebo, and all study volunteers will be encouraged to continue to return to their study sites on a regular basis for ongoing risk reduction counseling and study-related tests.
Similar news · Read more »
HIV therapy in pregnancy-data support WHO recommendations
08-20-2007 · EurekAlert!
In an observational cohort study from Côte d'Ivoire, François Dabis and colleagues report on prevention of mother-to-child HIV transmission among women receiving antiretroviral therapy according to World Health Organization recommendations.
Similar news · Read more »
Virus used to create experimental HIV vaccines directly impairs the immune response
11-15-2007 · EurekAlert!
Leading efforts to create an HIV vaccine have hinged on the use of viruses as carriers for selected elements of the HIV virus. Recently, however, evidence has emerged that some of these so-called viral vector systems may undermine the immune system and should not be used for vaccine development. Now, a new study from scientists at the Wistar Institute provides strong support for the idea that some viral-vector vaccines may cause more harm than good.
Similar news · Read more »
Arctic ice retreats into uncharted territory
09-27-2007 · EurekAlert!
On Oct. 1, the National Snow and Ice Data Center will issue a report summarizing the 2007 Arctic sea ice season, and NASA will issue a press release on a new sea ice study by NASA/JPL researchers. NASA has created new images in support of these and other reports about the remarkable decrease in sea ice this summer.
Similar news · Read more »
Chronic HIV-1 infection frequently fails to protect against superinfection
11-15-2007 · EurekAlert!
Natural HIV-1 infection does not always elicit a protective immune response, according to a new study published Nov. 16 in PLoS Pathogens. The team of researchers show how HIV-1 vaccines may not be as reliable against superinfection as once thought. This study suggests that immune responses found in natural HIV-1 infection may not be the best path to an effective HIV-1 vaccine.
Similar news · Read more »
Alpharma presents Phase 2 results of investigational abuse-deterrent opioid ALO-01
10-15-2007 · EurekAlert!
Alpharma Pharmaceuticals LLC, a subsidiary of Alpharma Inc., a leading global specialty pharmaceutical company, presented results from a Phase 2 study that showed ALO-01, an extended-release morphine sulfate plus sequestered naltrexone, provided similar effectiveness to KADIAN (morphine sulfate extended-release) capsules in osteoarthritis patients with moderate-to-severe chronic pain. The data were presented at the annual meeting of the American Society of Anesthesiologists in San Francisco, Calif., on Oct. 15, 2007.
Similar news · Read more »